DexTech Medical (DEX) Q1 26/27 earnings summary

Executive summary

• October CSR for the OsteoDex Phase I/IIa multiple myeloma study confirmed primary and secondary endpoints: no serious related adverse events and stable disease in all patients during treatment.

• More than 70% of patients maintained stable disease after treatment, in some cases for up to 30 weeks; results support continued development and partner discussions.

Financial highlights

• Q1 net sales were MSEK 0.0; operating profit and profit after tax were MSEK -1.5 (-1.3); EPS was SEK -0.08 (-0.07).

• Operating expenses were MSEK 1.8 (2.2), including MSEK 0.3 (0.8) capitalized for drug development and patents; cash flow for the period was MSEK -1.0 (-0.6).

Outlook and guidance

• Board assessment: current liquidity and unchanged business plan support operations at least through end-2028.

• Continued development, including a potential Phase III mCRPC study, is resource-intensive and requires an industrial partner; partnership work is ongoing.